Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Naphazoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.80 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.80 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.80 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.80 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.80 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naphazoline SCHEMBL29389276 | 1.00 | TAAR1 (0.80) | TAAR1CYP2D6NISCHLMNAMAPK1 | |
| Naphazoline SCHEMBL34532 | 0.89 | TAAR1 (1.00) | TAAR1CYP2D6NISCHLMNAMAPK1 | |
| Naphazoline SCHEMBL29369882 | 0.89 | TAAR1 (1.00) | TAAR1CYP2D6NISCHLMNAMAPK1 | |
| Naphazoline SCHEMBL26087856 | 0.88 | TAAR1 (0.97) | TAAR1CYP2D6NISCHLMNAMAPK1 | |
| Naphazoline SCHEMBL1649580 | 0.88 | TAAR1 (0.97) | TAAR1CYP2D6NISCHLMNAMAPK1 | |
| Naphazoline SCHEMBL24153 | 0.88 | TAAR1 (1.00) | TAAR1CYP2D6NISCHLMNAMAPK1 | |
| Naphazoline SCHEMBL12481545 | 0.88 | TAAR1 (0.97) | TAAR1CYP2D6NISCHLMNAMAPK1 | |
| Naphazoline SCHEMBL29389962 | 0.88 | TAAR1 (1.00) | TAAR1CYP2D6NISCHLMNAMAPK1 | |
| Naphazoline SCHEMBL28732221 | 0.87 | TAAR1 (0.84) | TAAR1CYP2D6NISCHLMNAMAPK1 | |
| Naphazoline SCHEMBL7039049 | 0.87 | TAAR1 (0.84) | TAAR1CYP2D6NISCHLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 662 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912545-A | Method for synthesizing and refining inorganic acid salt of naphazoline | 常州市天华制药有限公司 | 2022-01-11 | — | — | CN | claimed |
| US-20200038320-A1 | MULTIMODAL PARTICULATE FORMULATIONS | AEGIS THERAPEUTICS, LLC | 2020-02-06 | — | — | US | claimed |
| WO-2019155389-A1 | AN AQUEOUS MUCOADHESIVE AND BIOADHESIVE COMPOSITION FOR THE TREATMENT | TARGET ONCOLOGY INC. (US) | 2019-08-15 | — | — | WO | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| US-20170105934-A1 | AQUEOUS OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-20 | — | — | US | claimed |
| US-8840923-B2 | Slow-release pharmaceutical formulation and process for its preparation | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-09-23 | — | — | US | claimed |
| US-20140170220-A1 | MULTIMODAL PARTICULATE FORMULATIONS | HALE BIOPHARMA VENTURES, LLC (US) | 2014-06-19 | — | — | US | claimed |
| CN-101909608-B | A slow-release formulation based on an association of glycogen and alginate | ACRAF | 2013-01-23 | — | — | CN | claimed |
| EP-2234607-B1 | A SLOW-RELEASE FORMULATION BASED ON AN ASSOCIATION OF GLYCOGEN AND ALGINATE | ACRAF (IT) | 2011-08-03 | — | — | EP | claimed |
| CN-101909608-A | A slow-release formulation based on an association of glycogen and alginate | ACRAF | 2010-12-08 | — | — | CN | claimed |
| WO-2003015748-A2 | MUCOADHESIVE ERODIBLE DRUG DELIVERY DEVICE FOR CONTROLLED ADMINISTRATION OF PHARMACEUTICALS AND OTHER ACTIVE COMPOUNDS | ACCESS PHARMACEUTICALS, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| US-6159498-A | WATER-SOLUBLE DELIVERY DEVICE FOR APPLICATION TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 2000-12-12 | — | — | US | claimed |
| EP-0694310-B1 | REVERSIBLE, THERMALLY GELLING WATER-BASE MEDICINAL COMPOSITION | WAKAMOTO PHARMA CO LTD (JP) | 2000-02-16 | — | — | EP | claimed |
| CN-1198323-A | Microstructure composition | CIBA GEIGY AG (CH) | 1998-11-11 | — | — | CN | claimed |
| US-5624962-A | FOR OPHTHALMIC, DERMATOLOGICAL AND BADY CAVITICAL USE | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1997-04-29 | — | — | US | claimed |
| EP-0694310-A1 | REVERSIBLE, THERMALLY GELLING WATER-BASE MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1996-01-31 | — | — | EP | claimed |
| EP-0420798-B1 | Antimicrobial compositions | CIBA VISION AG (CH) | 1994-03-23 | — | — | EP | claimed |
| EP-0023359-B1 | POWDERY PHARMACEUTICAL COMPOSITION AND POWDERY PREPARATION FOR APPLICATION TO THE NASAL MUCOSA, AND METHOD FOR ADMINISTRATION THEREOF | TEIJIN LIMITED (JP) | 1984-04-18 | — | — | EP | claimed |
| US-4294829-A | Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereof | TEIJIN LIMITED (JP) | 1981-10-13 | — | — | US | claimed |
| EP-0023359-A2 | Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereof | TEIJIN LIMITED (JP) | 1981-02-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | ADRA2A 1458/4885ADRA2B 2044/4885ADRA2C 1373/4885 |
| US-20200038320-A1 | MULTIMODAL PARTICULATE FORMULATIONS | MTNR1B, MTNR1A, SERPINA6 | ADRA2A 570/4885ADRA2B 357/4885ADRA2C 475/4885 |
| US-20140170220-A1 | MULTIMODAL PARTICULATE FORMULATIONS | MTNR1B, MTNR1A, SERPINA6 | ADRA2A 570/4885ADRA2B 357/4885ADRA2C 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.